Education
About Us
Working with TipRanks
Follow Us
Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX
Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Rating:64Neutral
Price Target:
$5.00
▲( 7.99% Upside)
Positive Factors
Cost Management
Management's focus on long-term seed trait development and biologicals is expected to save approximately $5M annually, benefiting cash flow and reducing operating expenses.
Market Expansion
The EPA approved Bioceres’ registration of Rinotec, expanding the technology into the US market, enhancing their position in the alternative pesticides market in the US and Brazil.
Partnership Opportunities
Bioceres’ internal initiatives have expanded the international growth opportunity of its core businesses, with expectations for a significant contribution from their distribution agreement with Syngenta.
Negative Factors
Geographical Challenges
Q2’25 results met pre-released figures, with weakness across each segment but geographically concentrated in Argentina.
Market Reaction
Shares fell 14%, which is attributed to an ambiguous 2H’25 outlook.
Revenue Decline
Bioceres Crop Solutions reported revenues of $60.6M, down 28% year-over-year, and an adjusted EBITDA of $9M, down approximately 57% year-over-year.
Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.08M
Dividend YieldN/A
Average Volume (3M)113.61K
Price to Earnings (P/E)193.5
Beta (1Y)0.57
Revenue Growth-13.98%
EPS Growth-403.35%
CountryUS
Employees400
SectorBasic Materials
Sector Strength64
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.02
Shares Outstanding62,710,846
10 Day Avg. Volume126,900
30 Day Avg. Volume113,613
Financial Highlights & Ratios
PEG Ratio-447.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.17Price Target Upside54.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bioceres Crop Solutions Business Overview & Revenue Model
Company DescriptionBioceres Crop Solutions (BIOX) is an agricultural biotechnology company focused on providing innovative and sustainable solutions for crop productivity. It operates primarily in the sectors of seed technology, crop nutrition, and crop protection. The company's core products include genetically modified seeds, biological inoculants, and micro-beaded fertilizers designed to enhance crop yields and resilience.
How the Company Makes MoneyBioceres Crop Solutions makes money through the sale of its agricultural biotechnology products, which include genetically modified seeds engineered for higher yields and resistance to environmental stresses. Additionally, the company generates revenue from biological inoculants that improve soil health and crop productivity, and from micro-beaded fertilizers that offer efficient nutrient delivery. Key revenue streams include direct sales to farmers and agricultural distributors. The company also benefits from strategic partnerships and collaborations with other agricultural firms and research institutions, which help in the development and distribution of its products.
Bioceres Crop Solutions Financial Statement Overview
Summary
Bioceres Crop Solutions shows strong gross profitability and manageable leverage. However, the company faces challenges with revenue decline and low net profitability. Additionally, negative free cash flow indicates liquidity concerns. Overall, the financial standing is stable, but there is room for growth and efficiency improvements.Income Statement
Bioceres Crop Solutions' income statement demonstrates growth and stability. The company exhibits a strong gross profit margin of 42.1% TTM, indicating effective cost management, with stable EBIT and EBITDA margins of 7.8% and 10.8% respectively. However, revenue has declined by 12.3% from the previous annual report, and the net profit margin is relatively low at 0.6%, suggesting limited profitability.72
Positive
Balance Sheet
The balance sheet presents a moderate financial structure with a debt-to-equity ratio of 0.92, reflecting manageable leverage. The equity ratio of 37.1% TTM indicates a balanced asset financing mix. Return on equity is low at 0.8% TTM, signaling potential inefficiencies in generating profit from shareholders' equity.65
Positive
Cash Flow
Cash flow analysis reveals challenges with negative free cash flow of -$17.9 million TTM and operating cash flow to net income ratio of -1.7, suggesting potential liquidity issues. Despite these concerns, the company has shown past instances of positive free cash flow and operating performance, indicating potential for improvement.55
Neutral
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 407.71M | 464.83M | 419.45M | 328.46M | 206.70M | 172.35M | Gross Profit |
| 171.58M | 181.59M | 180.25M | 126.44M | 90.88M | 79.49M | EBIT |
| 31.65M | 44.82M | 54.18M | 39.87M | 38.38M | 39.15M | EBITDA |
| 43.86M | 55.46M | 61.09M | 40.03M | 37.04M | 29.58M | Net Income Common Stockholders |
| 2.57M | 3.24M | 18.78M | -7.20M | -6.87M | 3.36M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 32.90M | 56.17M | 60.05M | 38.61M | 46.78M | 51.57M | Total Assets |
| 837.00M | 850.63M | 818.06M | 518.22M | 394.59M | 297.56M | Total Debt |
| 270.70M | 270.95M | 257.41M | 169.79M | 174.58M | 149.09M | Net Debt |
| 254.30M | 226.47M | 209.28M | 136.31M | 138.53M | 106.57M | Total Liabilities |
| 504.10M | 501.06M | 487.56M | 359.92M | 304.30M | 236.81M | Stockholders Equity |
| 313.40M | 314.01M | 298.85M | 127.61M | 67.74M | 46.18M |
| Cash Flow | Free Cash Flow | ||||
| -17.93M | 18.93M | -19.97M | -26.51M | -20.13M | 4.82M | Operating Cash Flow |
| -4.37M | 41.72M | 2.59M | -17.52M | -6.21M | 9.32M | Investing Cash Flow |
| -6.78M | -28.73M | -25.73M | 2.90M | -8.31M | -7.80M | Financing Cash Flow |
| 18.76M | -10.06M | 32.95M | 14.82M | 7.36M | 33.53M |
Bioceres Crop Solutions Technical Analysis
Positive
4.63
Price Trends
4.38
Positive
5.08
Negative
6.46
Negative
Market Momentum
0.07
Negative
54.35
Neutral
38.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Positive. The current price of 4.63 is above the 20-day moving average (MA) of 4.47, above the 50-day MA of 4.38, and below the 200-day MA of 6.46, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 54.35 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024
Bioceres Crop Solutions Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $284.08M | 193.48 | 0.51% | ― | -13.98% | -403.35% | |
64 Neutral | $482.47M | ― | -35.32% | ― | 0.63% | -369.50% | |
55 Neutral | $122.64M | ― | -8.43% | 2.82% | -2.35% | -782.69% | |
55 Neutral | $3.51B | 121.47 | 4.98% | 4.34% | 0.75% | ― | |
55 Neutral | $5.71M | ― | -7.89% | ― | -2.81% | 72.03% | |
50 Neutral | $1.99B | -1.06 | -21.34% | 3.71% | 2.03% | -30.65% | |
46 Neutral | $297.15M | ― | -69.68% | ― | ― | ― |
* Basic Materials Sector Average
Performance Comparison
BIOX
Bioceres Crop Solutions
4.63
-6.32
-57.72%
AVD
American Vanguard
4.14
-4.69
-53.11%
IPI
Intrepid Potash
36.63
9.00
32.57%
SMG
Scotts Miracle-Gro Company
59.42
-3.55
-5.64%
RKDA
Arcadia Biosciences
4.28
1.36
46.58%
LVRO
Lavoro Limited
2.40
-3.41
-58.69%
Bioceres Crop Solutions Earnings Call Summary
Earnings Call Date:May 21, 2025
(Q3-2025)
| % Change Since: -0.43%|
Next Earnings Date:Sep 11, 2025
Earnings Call Sentiment Neutral
Bioceres Crop Solutions experienced significant challenges this quarter, primarily due to the absence of the prior year's Syngenta payments and a slow market in Argentina. However, the company achieved exceptional cash flow performance and received important regulatory approvals for Rinotec, positioning it for future growth. The highlights and lowlights are fairly balanced this quarter.Q3-2025 Updates
Positive Updates
Exceptional Cash Flow Performance
Bioceres reported a $40 million improvement in cash flow year-over-year, helping reduce debt and improve cash position.
Approval of Rinotec
Long-awaited EPA approval of Rinotec, allowing Bioceres to offer a full suite of biological solutions for pest control and plant health globally.
Growth in Seed and Integrated Products
Revenues in seed and integrated products increased by 26%, primarily fueled by accelerated sales of HB4 grain.
Successful Cash Management
Net cash from operating activities reached $23.3 million, a $40.7 million improvement compared to the previous year.
Positive Developments in U.S. and Mexico
U.S. and Mexico markets showed good growth, with early signs of recovery and stabilization in certain areas.
Negative Updates
Revenue Decline
Total revenues fell to $60.6 million from $84 million the previous year, largely due to the absence of a $16 million accrual from Syngenta's initial down payment.
Gross Profit Decrease
Gross profit dropped to $24 million from $42.6 million last year, primarily affected by the absence of the Syngenta payment.
Challenges in Argentina
Argentina experienced a slow third quarter with reduced commercial activity and seasonality impacting revenues.
Adjusted EBITDA Decline
Adjusted EBITDA fell to $9 million from $21.1 million last year, impacted by the absence of the Syngenta on-payment accrual.
Company Guidance
In the Bioceres Crop Solutions Fiscal Third Quarter 2025 earnings call, several key metrics and achievements were highlighted. Notably, the company reported a $40 million year-over-year improvement in cash flow, which played a significant role in reducing debt and enhancing the cash position. Despite a drop in total revenues to $60.6 million from $84 million the previous year, primarily due to the absence of a $16 million accrual from a Syngenta collaboration, the company maintained a consistent gross margin close to historical levels. The adjusted EBITDA for the quarter was $9 million, down from $21.1 million the previous year, but efforts to streamline the seed business and overall cost structure are expected to yield future savings. The company's strategic focus on enhancing cash generation and capital allocation has been evident, with a notable $23.3 million net cash from operating activities reported, marking a $40.7 million improvement from the previous year. Looking ahead, the launch of Rinotec and further penetration into conventional acreage markets are anticipated to drive future growth.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.